Prolactin receptor splice modulation shows preclinical promise in lupus
Published in Biology, Drugs development & discovery, Immunology, Journals.
Published November 2, 2026.
A study published today in Experimental & Molecular Medicine investigates alternative forms of the prolactin receptor as a potential target in systemic lupus erythematosus.
Rodrigues Lima-Junior and colleagues found an increased balance of long versus short receptor isoforms in lupus immune cells. A splice-modulating oligomer reduced the long form while increasing shorter forms.
In patient blood cells studied outside the body, the approach reduced several pathogenic immune-cell populations and interferon-related signals. Some changes varied between samples and did not reach significance across all patients. Tested healthy-donor cells did not show the same changes.
In lupus-prone mice, treatment reduced inflammatory signaling and prevented development of glomerular pathology under the experimental regimen. Prevention in this model does not demonstrate reversal of established kidney disease in people.
These findings support further investigation of receptor splicing, rather than a proven lupus treatment. Human safety and clinical effectiveness remain unestablished. The authors declare no competing interests. Earlier versions of this work circulated before today’s peer-reviewed publication.
Source: Rodrigues Lima-Junior et al., Experimental & Molecular Medicine, November 2, 2026.